Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression…
Read the full articleYou might also wanna read
China Wants To Cripple Anthropic
24/7 Wall St.·16h ago
Jim Cramer Says Broadcom Will Tell You When the Market Is About to Turn
24/7 Wall St.·16h ago
3 Semiconductor Stocks to Buy Before AI Demand Explodes in July
24/7 Wall St.·16h ago
NVIDIA Just Released a Seriously Impressive AI Model for Robots—This Could Be the Big Catalyst
24/7 Wall St.·16h ago
A $10,000 Investment in Cisco When Chuck Robbins Became CEO Is Worth This Much Today
24/7 Wall St.·17h ago
Boomers Swear by These High-Yield 5% and More Kings They Can Buy and Hold Forever
24/7 Wall St.·17h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.